01—Abstract
Summary
Summary of the 10-Q filed November 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported third-quarter 2026 total revenue of $982.7 milliona, a decrease of $22.1 million, or 2.2%, from $1,004.9 million a year earlier.
Nine-month revenue was $2,982.6 millionb versus $3,021.2 million, down 1.3%. The decline reflects the sale of the CDMO and Cell Solutions businesses and the European Discovery Services businesses, partly offset by growth in Microbial Solutions, Biologics Testing and regulated safety assessment. Operating income rose to $202.6 million (20.6% of revenue) for the quarter from $133.8 million (13.3%), and net income attributable to common shareholders increased to $333.1 million from $54.4 million, driven mainly by a $201 million tax benefit from the reversal of an unrecognized tax benefit reserve.
Diluted EPS for the quarter was $6.86c versus $1.10. The nine-month results included a $181.7 million pre-tax loss on the CDMO and Cell Solutions divestiture, which the company recorded within Other expense, net. Cash flow from operations was $474.9 million, down from $590.1 million, mainly due to higher variable compensation payments.
The company spent $467.3 milliond on acquisitions, including the Cambodian NHP Supplier and PathoQuest, and repurchased $300.0 million of stock, leaving $700.0 million available under its program. Total debt and finance leases rose to $2.46 billion, with the revolving facility balance at $943.2 million. Management announced the multi-year Create the Future restructuring program in September 2026, targeting more than $300 million of incremental annualized cost savings between 2027 and 2030.
The filing also discloses an ongoing putative securities class action and two stayed derivative lawsuits, all tied to importation of non-human primates. The company states it believes these claims are without merit and cannot reasonably estimate potential exposure or loss.
02—Key points
Key Highlights
- Total revenue of $982.7 million for the third quarter, down 2.2% from $1,004.9 million, primarily due to divestitures.
- Operating income of $202.6 million (20.6% of revenue) versus $133.8 million (13.3%) a year earlier.
- Net income attributable to common shareholders of $333.1 million, or $6.86 diluted EPS, boosted by a $201 million tax benefit from reversing an unrecognized tax benefit reserve.
- Nine-month results include a $181.7 million pre-tax loss on the CDMO and Cell Solutions divestiture.
- Operating cash flow of $474.9 million for the nine months, down from $590.1 million, mainly due to higher bonus payments and professional fees.
- Acquisitions of the Cambodian NHP Supplier ($507.3 million preliminary purchase price) and PathoQuest ($67.4 million) completed in 2026; $300.0 million of stock repurchased under a $1.0 billion program.
- Create the Future restructuring program announced in September 2026, with more than $300 million of incremental cost savings expected between 2027 and 2030.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 4, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $982.73M$1.00B | −2.2% |
| SG&A Expenses | $140.59M$177.59M | −20.8% |
| Operating Income | $202.64M$133.80M | +51.4% |
| Net Income | $333.07M$54.42M | +512.0% |
| EPS (Basic) | $6.97$1.11 | +527.9% |
| EPS (Diluted) | $6.86$1.10 | +523.6% |
| Shares Outstanding (Basic) | 47.80M49.21M | −2.9% |
| Shares Outstanding (Diluted) | 48.58M49.43M | −1.7% |
05—Questions
Frequently Asked Questions
Why did net income increase so sharply in the third quarter?
Net income attributable to common shareholders rose to $333.1 million from $54.4 million, mainly because of a $201 million tax benefit from reversing an unrecognized tax benefit reserve after a foreign tax law change and completion of certain tax requirements. Operating income also increased, driven by the CDMO divestiture benefit and lower accelerated amortization.
How much did the CDMO and Cell Solutions divestiture cost the company?
The company recognized a pre-tax loss on divestiture of $181.7 million for the nine months ended September 26, 2026, recorded within Other expense, net. This included a $118.0 million loss recognized in the first quarter when the businesses were classified as held for sale and a $63.7 million loss at closing in the second quarter. The sale generated $12.4 million in net cash paid to the buyer.
What is the status of the securities class action lawsuit?
The Oklahoma Firefighters Pension and Retirement System was appointed lead plaintiff on September 2, 2026, and filed a second amended complaint on September 15, 2026 that names only the Company and James Foster and narrows the class period. The Company filed a motion to dismiss on October 15, 2026, and plaintiff's opposition is due by November 16, 2026. The Company believes the claims are without merit and cannot reasonably estimate potential exposure.
How is the company funding acquisitions and share repurchases?
During the nine months, the company recorded net proceeds of $339.0 million, primarily from its Credit Facility, and used cash on hand. Total debt and finance leases increased to $2.46 billion from $2.15 billion at December 27, 2025, and the revolving facility balance rose to $943.2 million. Cash and cash equivalents were $200.4 million at quarter end, and the company repurchased $300.0 million of stock during the period.
06—Continue